NiharikaBansalMettuMDPhD

PubMed

• 1 citations
  Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
  Cho, D., Gibney, G., Hodi, F., Jones, M., Bowman, J., Smith, M., Lakshminarayanan, M., O'Day, S., Munster, P., Iannotti, N., Kirkwood, J., Villaruz, L., Mettu, N.> ;Cancer Research Communications. 2023 Dec 19
• 1 citations
  Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
  Ezra Rosen, Timothy A Yap, Elizabeth K Lee, Martin Højgaard, Niharika B Mettu, Stephanie Lheureux, Benedito A Carneiro, Ruth Plummer, Adrian J Fretland, Danielle Ulane...> ;Clinical Cancer Research. 2024 Feb 16
• 11 citations
  Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
  Timothy A Yap, Elisa Fontana, Elizabeth K Lee, David R Spigel, Martin Højgaard, Stephanie Lheureux, Niharika B Mettu, Benedito A Carneiro, Louise Carter, Ruth Plummer,...> ;Nature Medicine. 2023 Jun 1
• 2 citations
  Exploratory analysis of mesenteric-portal axis CT radiomic features for survival prediction of patients with pancreatic ductal adenocarcinoma.
  Francesca Rigiroli, Jocelyn Hoye, Reginald Lerebours, Peijie Lyu, Kyle J Lafata, Anru R Zhang, Alaattin Erkanli, Niharika B Mettu, Desiree E Morgan, Ehsan Samei, Danie...> ;European Radiology. 2023 Aug 1
• 5 citations
  Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
  Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
• 41 citations
  Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
  Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, Thorvardur R Halfdanarson, Heinz-Josef Lenz, Rimini A Breakstone, Patrick M Boland, Oxana V Crysler, Christina Wu, Andrew...> ;JAMA Network Open. 2022 Feb 1
• 24 citations
  A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
  Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert J. Stagg, Ann M. Kapoun, Leonardo...> ;Clinical Cancer Research. 2021 Nov 29
• 1 citations
  A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis
  Nicholas DeVito, Colm Kelleher, Kyle C. Strickland, James L. Abbruzzese, Carey K. Anders, Brent A. Hanks, Jingquan Jia, Niharika B. Mettu, Michael A. Morse, Margot O’N...> ;AME Case Reports. 2021 Apr 25
• 19 citations
  Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.
  Cara M. Kenney, Tricia F. Kunst, Santhana Webb, Devisser Christina, Christy Arrowood, Seth M. Steinberg, Niharika B. Mettu, Edward J. Kim, Udo Rudloff> ;Investigational New Drugs. 2021 Jan 6
• 64 citations
  Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
  Michael J. Overman, Milind Javle, Richard E. Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B. Mettu, Edwin R. Parra, Al B. Benson, Charles D. Lopez,...> ;Journal for Immunotherapy of Cancer. 2020 Feb 1
• 5 citations
  A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors
  Niharika B. Mettu, Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, Hope E. Uronis> ;Cancer Chemotherapy and Pharmacology. 2019 Mar 20
• 14 citations
  Clinical Insights Into the Biology and Treatment of Pancreatic Cancer
  Niharika B. Mettu, James L. Abbruzzese> ;Journal of Oncology Practice. 2016 Jan 1
• 9 citations
  Use of molecular biomarkers to inform adjuvant therapy for colon cancer.
  Niharika B. Mettu, Herbert Hurwitz, David S. Hsu> ;Oncology. 2013 Aug 15
• 1 citations
  Muehrcke's lines as a diagnostic clue to increased catabolism and a severe systemic disease state.
  John W. Stanifer, Reema Mehta, Niharika B. Mettu, Jeffrey Sanders, Noppon Setji> ;The American Journal of the Medical Sciences. 2011 Oct 1
• 30 citations
  The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors.
  Niharika B. Mettu, Thomas B. Stanley, Mary A. Dwyer, Michelle S. Jansen, John E. Allen, Julie M. Hall, Donald P. McDonnell> ;Molecular Endocrinology. 2007 Oct 1
• Join now to see all